Relay Therapeutics : June 2022 Corporate Presentation

Company Presentation

June 2022

Confidential | © 2022 Relay Therapeutics

1

Disclaimer

This presentation contains forward-looking statements and information about our current and future prospects and our operations and financial results, which are based on currently available information. All statements other than statements of historical facts contained in this presentation, including statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as ''aim,'' ''anticipate,'' ''assume,'' ''believe,'' ''contemplate,'' ''continue,'' ''could,'' ''design,'' ''due,'' ''estimate,'' ''expect,'' ''goal,'' ''intend,'' ''may,'' ''objective,'' "opportunity," ''plan,'' ''predict,'' ''positioned,'' ''potential,'' ''seek,'' ''should,'' ''target,'' ''will,'' ''would'' and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include express or implied statements about the initiation, timing, progress and results of our current and future clinical trials and current and future preclinical studies of our product candidates; the timing of disclosures regarding our pipeline and additional clinical data for RLY-4008 and initial clinical data for RLY-2608; the potential therapeutic benefits of our product candidates, including potential efficacy and tolerability, and combination potential of our product candidates; whether preliminary results from our preclinical or clinical trials will be predictive of the final results of the trials or any future clinical trials of our product candidates; the possibility that unconfirmed results from these trials will not be confirmed by additional data as the clinical trials progress; the competitive landscape and market opportunities for our product candidates; the expected strategic benefits under our collaborations; our ability to successfully establish or maintain collaborations or strategic relationships for our product candidates; expectations regarding current and future interactions with the U.S. Food and Drug Administration (FDA); our ability to manufacture our product candidates in conformity with the FDA's requirements; the capabilities and development of our DynamoTM platform; our financial performance; the effect of the COVID-19 pandemic, including mitigation efforts and economic effects, on any of the foregoing or other aspects of our business operations, including but not limited to our preclinical studies and future clinical trials; our plans to develop, manufacture and commercialize our current product candidates and any future product candidates; and the implementation of our business model and strategic plans for our business, current product candidates and any future product candidates.

Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make due to a number of risks and uncertainties. These and other risks, uncertainties and important factors are described in the section entitled "Risk Factors" in our most recent Annual Report on Form 10-K or most recent Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent our views only as of the date of this presentation and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, the occurrence of certain events or otherwise. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party studies, publications, surveys and other data to be reliable as of the date of this presentation, we have not independently verified, and make no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of our internal estimates or research and no reliance should be made on any information or statements made in this presentation relating to or based on such internal estimates and research.

This presentation contains trademarks, trade names and service marks of other companies, which are the property of their respective owners.

Confidential | © 2022 Relay Therapeutics

2

Relay Tx - Patient-Driven & Execution Focused

New Breed of Biotech	Validated Approach
				Clinical
			FGFR2	PI3KαPAN	SHP2
			RLY-4008	RLY-2608	RLY-1971
EXPERIMENTATION		COMPUTATION		Pre-clinical
			PI3KαPAN	Selective	ERα
			RLY-5836	CDK2	Degrader
Clear Focus			Execution-Focused
Validated	Therapeutic	Modalities
Targets	Areas
Innovators	Oncology	Small molecules
Challengers	Genetic diseases	Degraders

Confidential | © 2022 Relay Therapeutics

3

Relay Tx - Created by the Nexus of 3 Unstoppable Forces and Data

Increasing

Genomic

data

Improving

Experimental

insight

Increasing

Computational

power

1990

Data

Data

Data

INTEGRATION

Motion-Based

Drug Design™

Increasing efficiency and effectiveness of drug discovery

Confidential | © 2022 Relay Therapeutics

4

Relay Tx - Understanding Next Generation Drug Discovery: 4 Questions

The "What"

Whatproblems do we work on?

The "Where"

Wheredo we focus?

EXPERIMENTATIONCOMPUTATION

Modulation	Hit	Lead
Hypothesis	Identification	Optimization

The "How"

Howdo we work to solve problems?

PEOPLE

The Impact

How do we measure output?

Confidential | © 2022 Relay Therapeutics

5